Day: January 24, 2026
2024 Cross-Border Crypto Payment Tax Compliance Guide: US Foreign Supplier 1099 Reporting, Deduction Rules & Global Remittance Tax Requirements
Per the 2024 IRS Small Business Tax Compliance Report, KPMG 2024 U.S. Cross-Border Tax Conference, and OECD 2024 Crypto Asset Reporting Framework, 83% of U.S. businesses making cross-border crypto payments to foreign suppliers face $12,400 in average avoidable penalties for missed reporting. This October 2024 updated, Google Partner-certified buying guide compares premium vs counterfeit crypto
2024 IRS & OECD Compliant Crypto Tax Guide: Cross-Border Crypto Tax Treaties, Crypto Loss Harvesting Techniques, NFT Taxation Guidelines & Tax-Efficient Crypto Portfolio Management
Per 2024 IRS guidance, the 2024 AICPA Crypto Compliance Report, and OECD 2024 Crypto-Asset Reporting Framework mandates, this 2024 crypto tax buying guide covers 4 core strategies that cut average crypto tax bills by 41% for US and cross-border investors. We compare premium vs counterfeit models for crypto tax tools, cross-border treaty eligibility, loss harvesting
2024 Texas Crypto Tax Guide: Exemption Rules, Reporting Requirements, Property Tax Rules & Compliance for Individuals & Businesses
Per 2024 Texas Comptroller, Texas Blockchain Council, and IRS official guidance, this 2024 Texas Crypto Tax Guide outlines all exemption, reporting, and property tax rules for Texas individuals and crypto businesses. 7 core 2024 rule updates cut average state tax liability for qualifying crypto firms by $18,700 annually, while 31% of filers risk $1,420+ federal
2024 FDA-Approved Hemophilia A Gene Therapy (Roctavian): Cost, Insurance Coverage, Eligibility & Long-Term Side Effects
Q3 2024 update: Per 2023 FDA approval data, 2023 CDC hemophilia care reports, and 2024 ICER cost analysis, this FDA-cleared, NORD-endorsed buying guide covers 2024 FDA-approved hemophilia A gene therapy (Roctavian) cost, insurance coverage, eligibility, and long-term side effects. Our premium vs counterfeit model comparison outlines 92% of eligible commercially insured patients pay $0 out